Navigation Links
Karmanos Cancer Institute Seeks Breast Cancer Patients to Participate in a New Drug Trial
Date:11/10/2008

DETROIT, Nov. 10 /PRNewswire-USNewswire/ -- The Barbara Ann Karmanos Institute is looking for women with HER2 positive metastatic breast cancer to participate in a clinical trial.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO)

The Phase II trial at Karmanos is part of an international study to further test a new drug Trastuzumab-DM1, in development by Genentech. The trial will be under the direction of Patricia LoRusso, D.O., Karmanos director of the Phase I Clinical Trials Program and professor of internal medicine at Wayne State University.

"We are actively recruiting women to join this study and encourage them to call us for additional information," said Dr. LoRusso. She stated that eligible patients must have HER2 positive metastatic breast cancer, tumors measurable by radiographic evaluation, progressed on Herceptin, Tykerb and Xeloda, and show no current evidence of brain cancer.

Patients should call the Karmanos Clinical Trials office at 313-576-8749.

Dr. LoRusso has developed the Phase I program at Karmanos, one of only 14 National Cancer Institute (NCI)-funded Phase I programs in the country, and the only such program in Michigan. She has been integrally involved in the early clinical development of several drugs that are now commercially available.

The Barbara Ann Karmanos Cancer Institute

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 41 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D., is the Institute's president and chief executive officer. For more information call 1-800-KARMANOS or go to http://www.karmanos.org.


'/>"/>
SOURCE Karmanos Cancer Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Danialle Karmanos Work It Out (DKWIO) Site Earns Recognition for Web Excellence
2. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan
3. J.P. McCarthy Fund Grants $250,000 to Karmanos Cancer Institute
4. Karmanos Cancer Center Partners With Meadowbrook to Expand Outreach and Access for Cancer Services
5. Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
6. McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute
7. Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27
8. Kroger Pink Tag Campaign Raises $137,500 for Breast Cancer Research and Awareness at Karmanos Cancer Institute
9. Danialle Karmanos Work It Out Launches Dynamic Blog
10. Karmanos Cancer Center Most Preferred Hospital for Cancer Care According to 2007 Survey
11. Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology: